Main Objectives:

• To identify a biomarker matrix sensitive to pharmacological intervention with compounds currently approved for the treatment of Alzheimer’s Disease suitable to support pre-clinical PK/PD studies
• To test the sensitivity of the biomarker matrix by conducting studies using pharmacological tool compounds with novel mechanisms of action.
• To establish mathematical models describing the relationship between drug exposure and biomarker response to support clinical dose predictions
• To develop and validate the novel touch screen technology as a model with greater higher throughput, sensitivity and. translational capacity compared to traditional cognitive paradigms

WP Leads

Industry Lead: Dr John Atack (J&J) and Dr. Esther Schenker (Servier)

WP Partners:

• UnivMed, France
• University of Verona, Italy
• University of Foggia, Italy
• Mario Negri Institute, Italy
• GSK
• Boeringher
• Merck
• Lilly
• J&J
• Lundbeck
• Eisai Ltd